OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory filings.
Importance Rank:
1
OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory filings.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.